FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
See FITC spectral data
Cat # Size Price Quantity Avail. Save
100509 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  3. Zhang J, et al. 2018. Nature. 553:91. PubMed
  4. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  5. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  6. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  7. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  8. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  9. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  10. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  11. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  12. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  13. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  14. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  15. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  16. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  17. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  18. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  19. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  20. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  21. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  22. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  23. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  24. Papa I, et al. 2017. Nature. 547:318. PubMed
  25. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  26. Wan X, et al. 2018. Nature. 560:107. PubMed
  27. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  28. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  29. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  30. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  31. Kim M, et al. 2018. Immunity. 49:151. PubMed
  32. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  33. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  34. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  35. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  36. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  37. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  38. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  39. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  40. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  41. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  42. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  43. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  44. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  45. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  46. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  47. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  48. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  49. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  50. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  51. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  52. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  53. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  54. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01/29/2013

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account